News | January 24, 2025
Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Investment will fund expansion to meet rising demand for CRDMO services
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
Increases speed to market for drug developers working on nucleic acid therapeutics
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Subscribe To Our Newsletter & Stay Updated
